Trials / Withdrawn
WithdrawnNCT01240941
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Phase II Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II Trial of MK-2206 in combination with Endocrine Therapy in patients with Hormone Receptor Breast Cancer. After the maximum tolerated dose is determined in the phase 1b trial (under a separate NCT number), efficacy will be evaluated among 17 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-2206 | dose to be determined on the Phase 1b trial (listed under a separate NCT number) |
| DRUG | Exemestane | 25 mg orally daily |
| DRUG | Goserelin | 3.6 mg orally monthly |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-06-01
- Completion
- 2012-12-01
- First posted
- 2010-11-15
- Last updated
- 2013-08-20
Source: ClinicalTrials.gov record NCT01240941. Inclusion in this directory is not an endorsement.